Adverum's Losses Mount Amid R&D Surge, Going Concern Doubts

TL;DR

**Adverum is on life support, betting everything on the Lilly merger; if it fails, expect bankruptcy.**

AI Summary

Adverum Biotechnologies, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $143.86 million, a substantial rise from $89.99 million in the same period of 2024. This was primarily driven by a surge in research and development expenses, which more than doubled to $104.78 million from $52.94 million year-over-year. The company's cash and cash equivalents plummeted to $26.06 million as of September 30, 2025, from $60.65 million at December 31, 2024, with total current assets decreasing from $131.30 million to $28.91 million. Adverum also incurred a net cash outflow of $109.65 million from operating activities during the nine-month period. A critical risk highlighted is the pending merger with Eli Lilly and Company, which, if not completed, could force Adverum to wind down operations or seek bankruptcy protection. The company also faces substantial doubt about its ability to continue as a going concern, requiring significant additional funding to finance operations beyond regulatory approval of its lead program.

Why It Matters

This filing reveals Adverum Biotechnologies is in a precarious financial position, with a rapidly depleting cash reserve and a 'going concern' warning, making the pending merger with Eli Lilly a make-or-break event. For investors, the high risk of the merger failing, coupled with the potential for the Contingent Value Right (CVR) to expire valueless, means significant downside. Employees face uncertainty regarding job security if the merger collapses or if the company is forced into bankruptcy. Customers and the broader market for ocular gene therapies could see delays or termination of promising product candidates if Adverum cannot secure funding or complete the Lilly deal, impacting competitive dynamics in the biotech space.

Risk Assessment

Risk Level: high — The company explicitly states 'There is substantial doubt regarding our ability to continue as a going concern' and that if the pending merger with Eli Lilly and Company is not completed, 'we expect we would need to wind down our operations or seek bankruptcy protection.' Cash and cash equivalents decreased from $60.65 million to $26.06 million, and total current assets dropped from $131.30 million to $28.91 million, indicating severe liquidity issues.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the company's future hinges entirely on the successful completion of the Eli Lilly merger, which carries significant risks. New investors should avoid Adverum stock due to the explicit 'going concern' warning and the high probability of substantial losses if the merger fails.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$72.40M

total Debt

$128.05M

net Income

($143.86M)

eps

($6.59)

gross Margin

N/A

cash Position

$26.06M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $143.86M — Net Loss (9 months) (Increased from $89.99M in 2024, indicating worsening financial performance.)
• $104.78M — R&D Expenses (9 months) (More than doubled from $52.94M in 2024, driving increased losses.)
• $26.06M — Cash & Cash Equivalents (Significant decrease from $60.65M at year-end 2024, highlighting liquidity concerns.)
• $109.65M — Net Cash Used in Operations (Substantial cash burn for the nine-month period, unsustainable without external funding.)
• $1.2B — Accumulated Deficit (Reflects significant historical losses since inception, indicating lack of profitability.)
• ($55.65M) — Total Stockholders' (Deficit) Equity (Turned negative from $70.71M at year-end 2024, signaling severe financial distress.)
• 22,077,467 — Common Shares Outstanding (As of November 7, 2025, indicating potential for further dilution.)
• $2.03 — Net Loss Per Share (Q3 2025) (Increased from $1.55 in Q3 2024, reflecting higher losses per share.)

Key Players & Entities

• Adverum Biotechnologies, Inc. (company) — registrant
• Eli Lilly and Company (company) — pending merger partner
• $143.86 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $89.99 million (dollar_amount) — net loss for nine months ended September 30, 2024
• $104.78 million (dollar_amount) — research and development expenses for nine months ended September 30, 2025
• $52.94 million (dollar_amount) — research and development expenses for nine months ended September 30, 2024
• $26.06 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $60.65 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $109.65 million (dollar_amount) — net cash used in operating activities for nine months ended September 30, 2025
• $1.2 billion (dollar_amount) — accumulated deficit as of September 30, 2025

FAQ

Risk Factors

• Substantial Doubt About Going Concern [high — financial]: The company has incurred significant net losses, totaling $143.86 million for the nine months ended September 30, 2025, and has a substantial accumulated deficit of $1.21 billion. This, coupled with a sharp decline in cash and cash equivalents to $26.06 million and a net cash outflow from operations of $109.65 million, raises substantial doubt about its ability to continue as a going concern.
• Dependence on Eli Lilly Merger Completion [high — financial]: The pending merger with Eli Lilly and Company is critical. If the merger is not completed, Adverum may be forced to wind down its operations or seek bankruptcy protection, leading to a complete loss for stockholders.
• Deteriorating Liquidity Position [high — financial]: Cash and cash equivalents have fallen to $26.06 million as of September 30, 2025, a significant decrease from $60.65 million at December 31, 2024. Total current assets have also plummeted from $131.30 million to $28.91 million, indicating severe liquidity constraints.
• Increasing Operating Expenses [medium — financial]: Research and development expenses more than doubled to $104.78 million for the nine months ended September 30, 2025, from $52.94 million in the prior year period. This surge in R&D spending is a primary driver of the increased net loss.
• Negative Stockholders' Equity [high — financial]: Total stockholders' equity has turned negative, reaching a deficit of $55.65 million as of September 30, 2025, compared to a positive $70.71 million at December 31, 2024. This indicates that liabilities exceed assets.
• Need for Significant Additional Funding [high — operational]: The company requires substantial additional funding to finance its operations beyond the potential regulatory approval of its lead program. Without this funding, operations cannot continue.
• Dependence on Lead Program Success [high — market]: The company's future is heavily reliant on the successful development and regulatory approval of its lead gene therapy program. Any setbacks in clinical trials or regulatory review could have catastrophic consequences.
• High Cash Burn Rate [high — financial]: The company used $109.65 million in operating activities during the nine months ended September 30, 2025. This high cash burn rate is unsustainable without significant external financing or the successful completion of the Eli Lilly merger.

Industry Context

Adverum Biotechnologies operates in the highly competitive and capital-intensive gene therapy sector. This industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on groundbreaking scientific innovation and the ability to navigate complex clinical trials and regulatory pathways. The landscape includes large pharmaceutical companies and numerous smaller biotech firms vying for market share and investment.

Regulatory Implications

The company's gene therapy programs are subject to rigorous review by regulatory bodies like the FDA. Delays or failures in clinical trials or regulatory submissions can severely impact development timelines and financial viability. Compliance with evolving gene therapy regulations and manufacturing standards is critical for any potential product approval and market access.

What Investors Should Do

1. Monitor Eli Lilly Merger Status Closely
2. Assess Cash Runway and Burn Rate
3. Evaluate R&D Spending Efficiency
4. Consider Dilution Risk
5. Understand Going Concern Implications

Key Dates

• 2025-09-30: Nine Months Ended — Reported a net loss of $143.86 million and a significant increase in R&D expenses, highlighting deteriorating financial performance and high cash burn.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents stood at $26.06 million, and total stockholders' equity was a deficit of $55.65 million, indicating severe liquidity and solvency issues.
• 2024-12-31: Year-End Balance Sheet Date — Cash and cash equivalents were $60.65 million, and total stockholders' equity was positive at $70.71 million, showing a significant negative trend in the subsequent period.
• 2024-09-30: Nine Months Ended — Reported a net loss of $89.99 million and R&D expenses of $52.94 million, providing a baseline for the significant increase in losses and spending in 2025.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by net income or capital contributions. (Adverum has a substantial accumulated deficit of $1.21 billion, indicating a long history of unprofitability and significant losses.)

Going Concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company faces substantial doubt about its ability to continue as a going concern, a critical warning sign for investors regarding its survival.)

Cash and Cash Equivalents

Highly liquid investments with original maturities of three months or less at the time of purchase. (A sharp decline in cash and cash equivalents to $26.06 million signals potential difficulties in meeting short-term obligations.)

Operating Lease Right-of-Use Assets

An asset representing the right to use a leased asset over the lease term. (These assets, along with the corresponding lease liability, represent significant long-term obligations impacting the company's balance sheet.)

Additional Paid-In Capital

The amount investors have paid for stock above its par or stated value. (While substantial ($1.16 billion), it has not been enough to offset the large accumulated deficit.)

Net Loss Per Share

The portion of a company's profit or loss allocated to each outstanding share of common stock. (The increasing net loss per share ($2.03 in Q3 2025 vs. $1.55 in Q3 2024) reflects worsening profitability on a per-share basis.)

Stockholders' (Deficit) Equity

The residual interest in the assets of an entity after deducting all its liabilities. (A negative stockholders' equity of ($55.65 million) indicates that the company's liabilities exceed its assets, a sign of severe financial distress.)

Net Cash Used in Operating Activities

The amount of cash consumed by a company's normal business operations over a period. (A substantial outflow of $109.65 million highlights a significant cash burn that requires external funding.)

Year-Over-Year Comparison

Adverum Biotechnologies has experienced a significant financial deterioration compared to the prior year. Net loss has widened substantially to $143.86 million for the nine months ended September 30, 2025, from $89.99 million in the same period of 2024, primarily driven by a more than doubling of R&D expenses. Liquidity has severely eroded, with cash and cash equivalents dropping from $60.65 million at year-end 2024 to $26.06 million. Furthermore, stockholders' equity has turned negative, a stark contrast to its positive position last year, underscoring the increased financial distress and heightened risk factors.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value ADVM The NASDAQ Stock Marke

Filing Documents

• advm-20250930.htm (10-Q) — 1283KB
• advm-20250930ex101.htm (EX-10.1) — 105KB
• advm-20250930ex102.htm (EX-10.2) — 49KB
• advm-20250930ex103.htm (EX-10.3) — 57KB
• advm-20250930ex107.htm (EX-10.7) — 10KB
• advm-20250930ex311.htm (EX-31.1) — 10KB
• advm-20250930ex312.htm (EX-31.2) — 10KB
• advm-20250930ex321.htm (EX-32.1) — 5KB
• advm-20250930ex322.htm (EX-32.2) — 5KB
• image_1.jpg (GRAPHIC) — 25KB
• 0001628280-25-051593.txt ( ) — 5408KB
• advm-20250930.xsd (EX-101.SCH) — 31KB
• advm-20250930_cal.xml (EX-101.CAL) — 52KB
• advm-20250930_def.xml (EX-101.DEF) — 129KB
• advm-20250930_lab.xml (EX-101.LAB) — 487KB
• advm-20250930_pre.xml (EX-101.PRE) — 302KB
• advm-20250930_htm.xml (XML) — 498KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 5

Financial Statements

Item 1. Financial Statements 5 Condensed Consolidated Balance Sheets (unaudited) 5 Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) 6 Condensed Consolidated Statements of Stockholders' (Deficit) Equity (unaudited) 7 Condensed Consolidated Statements of Cash Flows (unaudited) 9 Notes to Condensed Consolidated Financial Statements (unaudited) 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 29

Controls and Procedures

Item 4. Controls and Procedures 29

—OTHER INFORMATION

PART II—OTHER INFORMATION 31

Legal Proceedings

Item 1. Legal Proceedings 31

Risk Factors

Item 1A. Risk Factors 31

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 79

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 79

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 79

Other Information

Item 5. Other Information 79

Exhibits

Item 6. Exhibits 80

SIGNATURES

SIGNATURES 82 2 Table of Contents RISK FACTORS SUMMARY Investing in common stock involves numerous risks, including the risks described in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. The pending merger with Eli Lilly and Company ("Lilly") is subject to a number of conditions beyond our control. We may not complete the merger within the time frame we anticipate or at all, which would have an adverse effect on our business, prospects, financial conditions, and results of operations, and we expect we would need to wind down our operations or seek bankruptcy protection. The pendency of the merger with Lilly could adversely affect our business, financial results and/or results of operations and may impair our ability to attract and retain qualified employees or retain or maintain relationships with our customers, suppliers, other business partners or governmental entities. While the Merger Agreement with Lilly is in effect, we are subject to certain restrictions on our business activities, and we have issued to Lilly a promissory note that contains additional restrictions on our operations, and if an event of default occurs under the promissory, Lilly can accelerate the entire principal amount and we would likely need to seek bankruptcy protection. Our stockholders may not receive any payment on the contingent value right ("CVR") and the CVR may expire valueless. We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which my adversely affect our operations and financial results. There is substantial doubt regarding our ability to continue as a going concern. We will need to raise substantial additional funding to finance our operations through regulatory approval of our lead program and beyon

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Adverum Biotechnologies, Inc. Condensed Consolidated Balance Sheets (In thousands) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,060 $ 60,652 Short-term investments — 65,039 Prepaid expenses and other current assets 2,849 5,609 Total current assets 28,909 131,300 Operating lease right-of-use assets 29,031 33,611 Property and equipment, net 10,462 11,607 Restricted cash 1,976 1,976 Deposit and other long-term assets 2,023 1,347 Total assets $ 72,401 $ 179,841 Liabilities and stockholders' (deficit) equity Current liabilities: Accounts payable $ 12,459 $ 1,610 Accrued expenses and other current liabilities 26,476 15,620 Lease liability, current portion 5,814 5,668 Total current liabilities 44,749 22,898 Long-term liabilities: Lease liability, net of current portion 83,126 86,037 Other non-current liabilities 179 192 Total liabilities 128,054 109,127 Commitments and contingencies (Note 4) Stockholders' (deficit) equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 1,155,598 1,138,070 Accumulated other comprehensive loss ( 440 ) ( 407 ) Accumulated deficit ( 1,210,813 ) ( 1,066,951 ) Total stockholders' (deficit) equity ( 55,653 ) 70,714 Total liabilities and stockholders' (deficit) equity $ 72,401 $ 179,841 See accompanying notes to condensed consolidated financial statements. 5 Table of Contents Adverum Biotechnologies, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 License revenue $ — $ 1,000 $ — $ 1,000 Operating expenses: Research and development $ 38,913 $ 20,439 $ 104,785 $ 52,946 General and administrative 9,110 14,999 41,314 44,595 Total operating expenses 48,023 35,438 146,099 97,541 Operating loss ( 48,023 ) ( 34,438 ) (

View Full Filing

View this 10-Q filing on SEC EDGAR